ssalz’s Activity

Tue Jul 21

NL

Boards Post

ssalz posted to the ISIS Pharmaceuticals board. 9:17 AM

Another first in the Science

Press Release: PR Newswire
Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease
Print CommentRecommend (0)
7-21-15 7:00 AM EDT | Email Article
First therapy designed to directly target the [more]

Mon Jul 20

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 9:00 AM

The beat continues on

Press Release: BusinessWire
Alnylam Initiates Phase 3 Open Label Extension Study (“APOLLO-OLE”) with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR [more]

Sun Jul 19

NL

Boards Post

ssalz posted to the Regulus Therapeutics, Inc. board. 3:09 PM

Starting on Alport Syndrome kidney disease

"Advancement of RG-012 into the clinic represents an important achievement under our 'Clinical Map Initiative' and further underscores our focus on discovering and developing novel microRNA therapies for orphan and rare diseases such as Alport [more]

Fri Jul 17

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 12:42 PM

What is this all about?????

Press Release: PR Newswire
Faruqi & Faruqi, LLP is Investigating Alnylam Pharmaceuticals, Inc. (ALNY) on Behalf of its Shareholders
Print CommentRecommend (0)
7-17-15 10:48 AM EDT | Email Article
NEW YORK, July 17, 2015 [more]

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 8:12 AM

A primer on RNAi

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as "a [more]

Mon Jul 6

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 7:20 PM

RNAi roundtable webcasts

Alnylam to Host Second Annual Summer “RNAi Roundtable” Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast its annual summer series of online [more]

Sat Jul 4

NL

Boards Post

ssalz posted to the ISIS Pharmaceuticals board. 8:39 PM

From the ISIS annual report July 1

<< Back
Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting
CARLSBAD, Calif., June 30, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following [more]

Wed Jun 24

NL

Boards Post

ssalz posted to the ISIS Pharmaceuticals board. 9:35 AM

Spinal Muscular Dystrophy

hildren treated with ISIS-SMN Rx
CARLSBAD, Calif., June 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 [more]

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 9:31 AM

Another plus Hemophilia RX

CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 23, 2015--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that new positive data from its ongoing Phase 1 clinical trial with ALN-AT3 -- an [more]

Tue Jun 23

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 8:52 AM

Complement mediated disease positive results

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced initial positive results from its ongoing Phase 1/2 clinical trial with ALN-CC5, an investigational RNAi therapeutic targeting complement component C5 [more]

Sat Jun 13

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 9:11 AM

ALNY and RX for complement mediated diseases

Press Release: BusinessWire
Alnylam Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases


This is also a big [more]

Thu Jun 11

NL

Boards Post

ssalz posted to the ISIS Pharmaceuticals board. 8:38 AM

ISIS and infant spinal musclar atrophy

Press Release: PR Newswire
Isis Pharmaceuticals Reports Data from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atrophy
Print CommentRecommend (0)
6-11-15 7:00 AM EDT | Email Article
Webcast to review study data scheduled [more]

Thu Jun 4

NL

Boards Post

ssalz posted to the Regulus Therapeutics, Inc. board. 8:51 AM

More on micro RNA's

About microRNAs

The discovery of microRNAs in humans during the last decade is one of the most exciting scientific breakthroughs in recent history. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not [more]

NL

Boards Post

ssalz posted to the Regulus Therapeutics, Inc. board. 8:43 AM

Alport's syndrome advance

LA JOLLA, Calif., June 4, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a [more]

Fri May 29

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 7:02 PM

Sorry

My last post (see above) had a lot of superfluous info. The important stuff is the last half of the post as it relates to the science of ALNY.

Thu May 28

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 9:36 AM

ALNY in WSJ for the first time (I think)

Alnylam Pharmaceuticals Inc. would consider performance-based pricing if its experimental rare-disease drugs reach the market, CEO John Maraganore said in an interview. The company’s lead drug in development is a treatment for a rare disease called [more]

Wed May 27

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 9:12 AM

Another new one

Tech Firms Seek Ways to Fend Off Activist Investors

Why LG’s Latest Android Watch Trails Apple’s

Are You Too Rigid?

A-HED
What’s Hot in the Art World? Algorithms

FIFA Officials Charged in Corruption [more]

Tue May 26

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 8:41 AM

More Science

– Company Expects to Present Initial Clinical Results in Early 2016 –

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 clinical trial with ALN-AS1, a [more]

Sun May 17

NL

Boards Post

ssalz posted to the Alnylam Pharmaceuticals board. 5:38 PM

The beat continues on

– Company Guides that it Plans to Initiate Phase 1/2 Trial in Late 2015 and Report Initial Clinical Results in Early 2016 –

– New Pre-Clinical Data with ALN-AAT Presented at Digestive Disease Week (DDW) Meeting, Showing Robust Knockdown of [more]

Thu May 14

NL

Boards Post

ssalz posted to the Berkshire Hathaway board. 10:26 AM

BRK and preventing train crashes

As USA Today noted 2 years ago, “Since 2005, the NTSB has investigated 15 train accidents in which 50 people were killed and 942 people were injured. In each case, the board concluded that positive train control would have prevented the [more]

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 0 out of 75193
Score 0.00
Score Change Today 0
Accuracy 0.00%
Active Picks 0
Total Picks 0
Best Pick ( 0)
Worst Pick ( 0)
Average Score per Pick 0.00
Charms Earned 0
Highest Rated Favorite No Favorites Selected
Go to ssalz’s CAPS page

Boards Stats & Trivia

Big red star, 1000 posts Old School Fool
Board Posts 1046
Recs Received 2269
People who have rec'd these posts 585
Recs to Posts Ratio (last 30 days) N/A
Threads Started 366
Threads Started Percentage 34.99 %
Most Frequent Board Berkshire Hathaway
Very First Post Re: Amgen valuation (6/8/1999)
Percentage of Posts Rec'd 51.34 %
Show ssalz’s 10 Latest Posts